期刊
JOURNAL OF CONTROLLED RELEASE
卷 270, 期 -, 页码 135-144出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2017.11.041
关键词
Nanoparticles; Microparticles; Chitosan amphiphiles; Leucine(5)-enkephalin; Intranasal; Analgesia; Brain delivery; Delta opioid receptor
资金
- UK Engineering and Physical Sciences Research Council [EP/K502340/1]
- Nanomerics Ltd. [NM12TSB-NPP]
- Innovate UK [16939-124181]
- EPSRC [EP/K502340/1, EP/L024748/1, EP/G061483/1] Funding Source: UKRI
- Engineering and Physical Sciences Research Council [EP/L024748/1, EP/G061483/1, GR/T20410/01, GR/T20410/02, EP/K502340/1] Funding Source: researchfish
The delivery of peptide drugs to the brain is challenging, principally due to the blood brain barrier and the low metabolic stability of peptides. Exclusive delivery to the brain with no peripheral exposure has hitherto not been demonstrated with brain quantification data. Here we show that polymer nanoparticles encapsulating leucine(5)-enkephalin hydrochloride (LENK) are able to transport LENK exclusively to the brain via the intranasal route, with no peripheral exposure and nanoparticle localisation is observed within the brain parenchyma. Animals dosed with LENK nanoparticles (NM0127) showed a strong anti-nociceptive response in multiple assays of evoked and on going pain whereas animals dosed intranasally with LENK alone were unresponsive. Animals did not develop tolerance to the anti-hyperalgesic activity of NM0127 and NM0127 was active in morphine tolerant animals. A microparticulate formulation of clustered nanoparticles was prepared to satisfy regulatory requirements for nasal dosage forms and the polymer nanoparticles alone were found to be biocompatible, via the nasal route, on chronic dosing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据